Pfizer and Divi's Laboratories outperformance was driven by better than expected revenue growth and margin expansion while Jubilant Pharmova, Dr. Reddy's and Zydus Lifesciences reported lower operational costs, thus aiding operating profit outperformance.NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.Systematix ReportCompanies under our coverage reported an in line Q4 FY25, with Divi Laboratories Ltd., Zydus Lifesciences, Pfizer, Dr. Reddy's Laboratories and Jubilant Pharmova Ltd. as outperformers on operating profit growth expectations and Indoco Remedies as the underperformer. Pfizer and Divi's Laboratories outperformance was driven by better than expected revenue growth and margin expansion while Jubilant Pharmova, Dr. Reddy's and Zydus Lifesciences reported lower operational costs, thus aiding operating profit outperformance. However, Indoco Remedies underperformed expectations due to higher costs. Our top picks are Sun Pharma, Cipla, Ajanta Pharma and Orchid Pharma. We discontinue coverage on Sastasundar Ventures and Indoco Remedies, considering the uncertainty around predicting their near term earnings owing to ongoing compliance challenges in case of Indoco Remedies and the transition of Sastasundar business into an online pharmacy.Click on the attachment to read the full report:Ceat's Integration Of Camso To Be A Key Monitorable, Says Motilal Oswal Maintaining 'Buy' DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.Users have no license to copy, modify, or distribute the content without permission of the Original Owner.. Read more on Research Reports by NDTV Profit.